Psychiatry & Neurology Doctors in Niles, IL Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Dr. Peter Lourgos, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 7447 W Lawler Ave, Niles, IL 60714 Phone: 855-629-0554    Fax: 888-947-7879

Dr. Michael Jay Wasserman, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 8780 W Golf Road, Suite 202, Niles, IL 60714 Phone: 847-298-4590    Fax: 847-298-0635

Zehra Ibrahim Rowjee, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 241 Golf Mill Professional Building, Suite #711, Niles, IL 60714 Phone: 847-299-2277    Fax: 847-998-8935

Dr. Abraham Kuruvilla, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 8333 W Maynard Rd, Niles, IL 60714 Phone: 313-744-0549    Fax: 248-918-0229

News Archive

AHF's first AIDS treatment center to open in Washington, DC

AIDS Healthcare Foundation (AHF), the US' largest non-profit HIV/AIDS healthcare provider, which provides medical care and/or services to more than 100,000 individuals in 21 countries worldwide, is honored to announce the September 24th grand opening of AHF's first AIDS treatment center in Washington, DC, where the HIV rate is now reported to be 3%—higher than the rate in Lagos, Nigeria. The health care center, AHF's first to be named in honor of Hollywood actor and longtime AIDS advocate Blair Underwood, will include a state-of-the-art, full-service HIV/AIDS treatment clinic as well as an on-site AHF Pharmacy. The facility will be known as the AHF Blair Underwood Clinic.

MassMutual's Retirement Services Division hires a new sales representative

MassMutual's Retirement Services Division has hired a new sales representative to support its growing Taft-Hartley business.

Humans can speed up their own evolution

A study by J. Todd Streelman, new assistant professor of biology at the Georgia Institute of Technology suggests that humans may have sped up the evolutionary clock for one species of fish.

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

Read more Medical News

› Verified 4 days ago